Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: A LIFE-BTK Pharmacokinetics Substudy

20250 citationsJournal Articlegold Open Access

Authors

Jen‐Kuang Lee · National Taiwan University Hospital

Richard Pin · Charlton Memorial Hospital

Shirley Jansen · Sir Charles Gairdner Hospital

Anderson Mehrle · Phillips 66 (United States)

Yazan Khatib · First Coast Cardiovascular Institute

Prakash Krishnan · Mount Sinai Hospital

Brian G. DeRubertis

Abstract

The present substudy assessed the PK of everolimus delivered by Esprit BTK in the planned treatment of narrowed infrapopliteal lesions. This study confirms that the PK profile of everolimus eluted from the Esprit BTK scaffold results in limited systemic exposure and is considered to be safe and well tolerated.

Topics & Keywords

Peripheral Artery Disease Management Angiogenesis and VEGF in Cancer Infectious Aortic and Vascular Conditions

Publication Details

Published in: Journal of the Society for Cardiovascular Angiography & Interventions

Volume 5, Issue 1, pp. 104107-104107

DOI: 10.1016/j.jscai.2025.104107

Field-Weighted Citation Impact: 0.00

Command Palette

Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: A LIFE-BTK Pharmacokinetics Substudy

Authors

Abstract

Topics & Keywords

Publication Details